Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-03T02:02:19.429Z Has data issue: false hasContentIssue false

Olanzapine-induced rhabdomyolysis

Published online by Cambridge University Press:  13 June 2014

Loopinder Sood
Affiliation:
St Michael's Hospital, St Michael's Road, Warwick, CV34 5QW
Andy Owen
Affiliation:
St Michael's Hospital, St Michael's Road, Warwick, CV34 5QW
Mandeep Saini
Affiliation:
Women's Forensic Mental Health Service, Adenleigh, Erdington, Birmingham, England

Abstract

We present a case of possible olanzapine-induced rhabdomyolysis in the absence of other features of neuroleptic malignant syndrome (NMS). There is evidence to suggest that there are different underlying pathophysiological mechanisms for rhabdomyolysis occurring alone, in contrast to when it presents as part of NMS. This has possible implications for drug rechallenge which is discussed.

Type
Case Reports
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Haddad, PM. Neuroleptic malignant syndrome: May be caused by other drugs. BMJ 1994; 308(6922): 200b.CrossRefGoogle ScholarPubMed
2.Poels, PJE and Gabreels, FJM. Rhabdomyolysis: a review of the literature. Clin Neurol and Neurosurg 1993; 95: 175192.CrossRefGoogle ScholarPubMed
3.Meltzer, HY, Cola, PA and Parsa, M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharm 1996; 15:395405.CrossRefGoogle ScholarPubMed
4.Sachdev, P, Kruk, J, Kneebone, M, Kissane, D. Clozapine-induced Neuroleptic Syndrome: Review and report of new cases. J Clin Psychopharm 1995; 15(5): 365371.CrossRefGoogle ScholarPubMed
5.Gabow, PA, Kaehny, WD, and Kelleher, SP. The spectrum of rhabdomyolysis. Medicine 1982;61:141–52.CrossRefGoogle ScholarPubMed